LAUSR

1. Spagnoli C, Salerno GG, Iodice A, Frattini D, Pisani F, Fusco C. KCNQ2 encephalopathy: A case due to a de novo deletion. Brain Dev 2018;40:65‐8. 2. Pisano T, Numis AL, Heavin SB, Weckhuysen S, Angriman M, Suls A, et al. Early and effective treatment of KCNQ2 encephalopathy. Epilepsia 2015;56:685‐91. 3. Srivastava S, Sahin M. Autism spectrum disorder and epileptic encephalopathy: Common causes, many questions. J Neurodev Disord 2017;9:23‐34. 4. Schubert‐Bast S, Hofstetter P, Fischer D, Schloesser R, Ramantani G, Kieslich M. Sodium channel blockers in KCNQ2‐encephalopathy: Lacosamide as a new treatment option. Seizure 2017;51:171‐3. 5. Malerba F, Alberini G, Balagura G, Marchese F, Amadori E, Riva A, et al. Genotype‐phenotype correlations in patients with de novo KCNQ2 pathogenic variants. Neurol Genet 2020;6:e528. 6. Millichap JJ, Park KL, Tsuchida T, Ben‐Zeev B, Carmant L, Flamini R, et al. KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol Genet 2016;2:e96. 7. Lepeta K, Lourenco MV, Schweitzer BC, Martino Adami PV, Banerjee P, Catuara‐Solarz S, et al. Synaptopathies: Synaptic dysfunction in neurological disorders‐A review from students to students. J Neurochem 2016;138:785‐805. 8. Kuersten M, Tacke M, Gerstl L, Hoelz H, Stülpnagel CV, Borggraefe I. Antiepileptic therapy approaches in KCNQ2 related epilepsy: A systematic review. Eur J Med Genet 2020;63:103628. 9. Mulkey SB, Ben‐Zeev B, Nicolai J, Carroll JL, Grønborg S, Jiang YH, et al. Neonatal nonepileptic myoclonus is a prominent clinical feature of KCNQ2 gain‐of‐function variants R201C and R201H. Epilepsia 2017;58:436‐45. 10. Kamate M, Detroja M. Uncommon treatable genetic epileptic encephalopathies. Indian Pediatr 2019;56:427‐8.